Your browser doesn't support javascript.
loading
Prospective Evaluation of Different Methods for Volumetric Analysis on [18F]FDG PET/CT in Pediatric Hodgkin Lymphoma.
Lopci, Egesta; Elia, Caterina; Catalfamo, Barbara; Burnelli, Roberta; De Re, Valli; Mussolin, Lara; Piccardo, Arnoldo; Cistaro, Angelina; Borsatti, Eugenio; Zucchetta, Pietro; Bianchi, Maurizio; Buffardi, Salvatore; Farruggia, Piero; Garaventa, Alberto; Sala, Alessandra; Vinti, Luciana; Mauz-Koerholz, Christine; Mascarin, Maurizio.
Afiliação
  • Lopci E; Nuclear Medicine Unit, IRCCS-Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
  • Elia C; AYA and Pediatric Radiotherapy Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
  • Catalfamo B; Nuclear Medicine Unit, University Hospital "Mater Domini, 88100 Catanzaro, Italy.
  • Burnelli R; Pediatric Onco-Hematologic Unit, University Hospital S. Anna, 44121 Ferrara, Italy.
  • De Re V; Immunopathology and Cancer Biomarkers Unit, Department of Translational Research, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
  • Mussolin L; Pediatric Hemato-Oncology Clinic, Department of Women's and Children's Health, University of Padua, 35128 Padua, Italy.
  • Piccardo A; Institute of Pediatric Research-Fondazione Città della Speranza, 35127 Padua, Italy.
  • Cistaro A; Department of Nuclear Medicine, Galliera Hospital, 16128 Genoa, Italy.
  • Borsatti E; Nuclear Medicine Division, Salus Alliance Medical, 16128 Genoa, Italy.
  • Zucchetta P; Nuclear Medicine Department, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
  • Bianchi M; Nuclear Medicine Department, Padova University Hospital, 35128 Padua, Italy.
  • Buffardi S; Onco-Hematology Division, Regina Margherita Hospital, 10126 Torino, Italy.
  • Farruggia P; Department of Oncology, Hospital Santobono-Pausilipon, 80123 Naples, Italy.
  • Garaventa A; Department of Pediatric Onco-Hematology, A.R.N.A.S. Ospedali Civico, 90127 Palermo, Italy.
  • Sala A; Pediatric Oncology Unit, I RCCS G.Gaslini Hospital, 16147 Genoa, Italy.
  • Vinti L; Pediatric Division, Hospital San Gerardo, 20900 Monza, Italy.
  • Mauz-Koerholz C; Department of Pediatric Hematology and Oncology, Ospedale Bambino Gesù, IRCSS, 00165 Rome, Italy.
  • Mascarin M; Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, 35392 Giessen, Germany.
J Clin Med ; 11(20)2022 Oct 21.
Article em En | MEDLINE | ID: mdl-36294544
Rationale: Therapy response evaluation by 18F-fluorodeoxyglucose PET/CT (FDG PET) has become a powerful tool for the discrimination of responders from non-responders in pediatric Hodgkin lymphoma (HL). Recently, volumetric analyses have been regarded as a valuable tool for disease prognostication and biological characterization in cancer. Given the multitude of methods available for volumetric analysis in HL, the AIEOP Hodgkin Lymphoma Study Group has designed a prospective analysis of the Italian cohort enrolled in the EuroNet-PHL-C2 trial. Methods: Primarily, the study aimed to compare the different segmentation techniques used for volumetric assessment in HL patients at baseline (PET1) and during therapy: early (PET2) and late assessment (PET3). Overall, 50 patients and 150 scans were investigated for the current analysis. A dedicated software was used to semi-automatically delineate contours of the lesions by using different threshold methods. More specifically, four methods were applied: (1) fixed 41% threshold of the maximum standardized uptake value (SUVmax) within the respective lymphoma site (V41%), (2) fixed absolute SUV threshold of 2.5 (V2.5); (3) SUVmax(lesion)/SUVmean liver >1.5 (Vliver); (4) adaptive method (AM). All parameters obtained from the different methods were analyzed with respect to response. Results: Among the different methods investigated, the strongest correlation was observed between AM and Vliver (rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at all scan timing), along with V2.5 and AM or Vliver (rho 0.98, p < 0.001 for TLG at baseline; rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at PET2 and PET3, respectively). To determine the best segmentation method, we applied logistic regression and correlated different results with Deauville scores at late evaluation. Logistic regression demonstrated that MTV (metabolic tumor volume) and TLG (total lesion glycolysis) computation according to V2.5 and Vliver significantly correlated to response to treatment (p = 0.01 and 0.04 for MTV and 0.03 and 0.04 for TLG, respectively). SUVmean also resulted in significant correlation as absolute value or variation. Conclusions: The best correlation for volumetric analysis was documented for AM and Vliver, followed by V2.5. The volumetric analyses obtained from V2.5 and Vliver significantly correlated to response to therapy, proving to be preferred thresholds in our pediatric HL cohort.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article